Table 1. POPF after pancreatoduodenectomy in the mandatory Dutch Pancreatic Cancer Audit in the period 2014–2018.
| Total, n | POPF grade B/C, n (%) | |
| Diagnosis | ||
| PDAC | 1453 | 113 (7.8) |
| Cholangiocarcinoma | 452 | 107 (23.7) |
| Papillary carcinoma | 443 | 85 (19.2) |
| Duodenal carcinoma | 214 | 45 (21.0) |
| NET | 170 | 42 (24.7) |
| IPMN, SPN, MCN | 276 | 42 (15.2) |
| Chronic pancreatitis | 110 | 7 (6.4) |
| Other, unknown | 359 | 66 (18.4) |
| Main pancreatic duct diameter | ||
| MPD ≤3 mm | 892 | 209 (23.4) |
| MPD >3 mm | 1232 | 86 (7.0) |
| Risk categories | ||
| PDAC and MPD >3 mm | 681 | 26 (3.8) |
| PDAC and MPD ≤3 mm | 297 | 47 (15.8) |
| Non-PDAC* and MPD >3 mm | 538 | 60 (11.2) |
| Non-PDAC* and MPD ≤3 mm | 590 | 162 (27.5) |
*
Non-PDAC: cholangiocarcinoma, papillary/ampullary carcinoma, duodenal carcinoma, NET, IPMN, SPN, MCN.
IPMN, intraductal papillary mucinous neoplasm (all types, including invasive IPMN); MCN, mucinous cystic neoplasm; MPD, main pancreatic duct diameterPDAC, pancreatic ductal adenocarcinoma; POPF, postoperative pancreatic fistula according to the ISGPS 2016 criteria; SPN, solid-pseudopapillary neoplasm